Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Evolus Inc (EOLS) raises full-year guidance on strong portfolio growth and strategic expansion into skin quality with Profhilo partnership.
Evolus (NASDAQ:EOLS) reported second-quarter revenue growth of 21% and raised the lower end of its full-year 2026 revenue outlook, citing market-share gains in neurotoxins and hyaluronic acid injectable gels, continued customer adoption of its portfolio and expanding international operations. Globa
Evolus (EOLS) delivered earnings and revenue surprises of +100.00% and +2.59%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Over the last 7 days, the United States market has risen by 1.1%, contributing to an impressive 27% climb over the past year, with earnings forecasted to grow by 17% annually. In this thriving environment, companies that exhibit high growth potential and significant insider ownership can be particularly appealing, as they often indicate strong confidence from those closest to the business.
Moby summary of Evolus, Inc.'s Q1 2026 earnings call
Evolus (EOLS) delivered earnings and revenue surprises of +25.93% and +0.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Evolus (NASDAQ:EOLS) reported first-quarter results that management said reflected a stronger operating model following cost structure changes implemented last year, while reiterating its full-year 2026 outlook for double-digit revenue growth and adjusted EBITDA profitability. First-quarter results
David Moatazedi: Thank you, Nareg, and good afternoon, everyone. Internationally, the business continues to deliver strong performance and is increasingly contributing to our growth trajectory as we expand our global footprint in key markets.
The latest analyst work on Evolus keeps the modeled fair value steady at US$14.67 per share, even as several firms reduce their published price targets. Those cuts are tied less to a change in the core valuation inputs and more to how analysts interpret the softer preliminary 2025 net revenue outlook, the 2026 guide, and the scaled back long term narrative. As you read on, you will see how to approach this evolving setup and what to watch as the story continues to develop. Stay updated as the...
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.